M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma

Letter Oncology

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Somayya Noori et al.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah Giles et al.

BLOOD (2022)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Management of Multiple Myeloma A Review

Andrew J. Cowan et al.

Summary: Multiple myeloma is a hematologic malignancy characterized by abnormal plasma cells in the bone marrow, often leading to anemia, bone disease, and kidney injury. Diagnosis involves measuring various biomarkers, while treatment options include chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance therapy.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Oncology

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

Binod Dhakal et al.

Summary: This study shows that tumor-informed ctDNA analysis is highly predictive of MM relapse, with a higher positive predictive value compared to traditional MFC-based MRD assessment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesus San-Miguel et al.

Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, daratumumab-based therapy reduces the risk of disease progression or death. MRD-negative status and sustained MRD negativity are associated with improved progression-free survival, and daratumumab-based therapy improves rates of MRD negativity lasting 6 or 12 months.

BLOOD (2022)

Add to Collection

Article Hematology

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Michele Cavo et al.

Summary: In this study, we explored the impact of minimal residual disease (MRD) on relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). The results showed that achieving complete response or better (>= CR) and MRD negativity were associated with improved progression-free survival (PFS) in both RRMM and TIE NDMM patients, regardless of the type of therapy or disease setting.

BLOOD (2022)

Add to Collection

Review Hematology

The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?

Hannah Giles et al.

Summary: Mass spectrometry techniques offer a highly sensitive method for evaluating and monitoring paraproteins compared to standard electrophoretic techniques, providing valuable insights for clinical assessment and clinical trial enrollment. The increased sensitivity of these assays helps detect and monitor monoclonal proteins more effectively and can increase detection rates of low-level monoclonal proteins.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Bringing mass spectrometry into the care of patients with multiple myeloma

David L. Murray

Summary: Serum protein electrophoresis methods are widely used for detecting M-proteins in multiple myeloma patients, but they have analytical limits and can be interfered by new therapeutic monoclonal antibody treatments. New mass spectrometry techniques are emerging with improved clinical and analytical performance, showing potential in the care of multiple myeloma patients.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients-A Proof of Concept

Rui Bergantim et al.

Summary: This study successfully detected measurable residual disease in samples from multiple myeloma patients by exploring biomarkers in extracellular vesicles. The findings highlight the potential of peripheral blood extracellular vesicles as a source of multiple myeloma biomarkers and a non-invasive approach for monitoring measurable residual disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Medical Laboratory Technology

Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab

Mindy Kohlhagen et al.

Summary: The study describes an automated Mass-Fix method based on MALDI-TOF MS as a replacement for traditional gel-based immunofixation. After validation, Mass-Fix meets the requirements of clinical laboratories, improving sample processing efficiency and identification accuracy, while reducing paper storage and resource waste.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

Add to Collection

Article Hematology

Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma

Jithma P. Abeykoon et al.

Summary: Simultaneous evaluation of MRD with NGF and MASS-FIX post ASCT shows higher accuracy in predicting prognosis of multiple myeloma patients. Patients who are NGF-negative but MASS-FIX-positive have lower survival and progression-free rates.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Medical Laboratory Technology

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Pieter Langerhorst et al.

Summary: The study shows that blood-based targeted mass spectrometry evaluation (MS-MRD) is a sensitive alternative for assessing prognosis and disease activity in multiple myeloma patients. MS-MRD is capable of detecting M-protein with higher sensitivity compared to traditional methods, and its potential clinical application warrants further validation in larger cohorts.

CLINICAL CHEMISTRY (2021)

Add to Collection

Article Medical Laboratory Technology

Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma

Pieter Langerhorst et al.

Summary: The research demonstrates the use of clonal immunoglobulin gene fingerprints as a suitable MRD target for MS-MRD analyses in patients with MM, offering promising clinical applications.

CLINICAL CHEMISTRY (2021)

Add to Collection

Article Oncology

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

David L. Murray et al.

Summary: Mass spectrometry is emerging as a powerful tool in diagnosing and monitoring plasma cell disorders, showing equivalent clinical performance to immunofixation electrophoresis with added benefits of detecting additional risk factors and differentiating therapeutic antibodies. This technology is gaining traction in clinical laboratories and may become the new standard in practice.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Letter Oncology

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Benjamin A. Derman et al.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Medical Laboratory Technology

Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy

Marion Eveillard et al.

Summary: The use of MALDI-TOF MS for detecting M-proteins is helpful in assessing complete response in patients treated with monoclonal antibody therapies.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Review Oncology

MRD Assessment in Multiple Myeloma: Progress and Challenges

Luca Bertamini et al.

Summary: In recent years, significant progress has been made in the assessment of MRD in multiple myeloma (MM). Achievement of MRD negativity is considered prognostically important and associated with better survival. Along with established techniques, other methods are under study, and the appropriate use of MRD assessment in therapeutic decision making remains a fascinating and challenging issue for clinicians.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

Add to Collection

Letter Oncology